Pengfei Li
   Translational researcher
   University Hospital
Fields of Expertise:
Virus-host interaction
POSITIONS
No position available




BIOGRAPHY

At the early stage of my research (Veterinary Medicine), I dedicated to investigating the epidemiology of emerging viruses among waterfowls in China, and developing specific preventive or therapeutic antivirals against these animal viruses. In 2018, I moved to The Nether... Read more

At the early stage of my research (Veterinary Medicine), I dedicated to investigating the epidemiology of emerging viruses among waterfowls in China, and developing specific preventive or therapeutic antivirals against these animal viruses. In 2018, I moved to The Netherlands and started my PhD research. Incorporating previous experience in animal diseases, my research interests have expanded to analyzing epidemiology of emerging cross-species viruses, studying virus-host interactions, as well as developing antiviral therapies. So far, I have contributed to more than 50 publications on these topics, with 17 publications as (co-)first author. My current research focuses on:

  1. Developing human-derived primary organoids based models, including liver organoids, intestinal organoids and airway organoids, for viral infections. Based on these 3D-constructed organoids, I aim to understand the pathogenesis, host responses and antiviral therapies against human rotavirus, hepatitis E virus, seasonal coronaviruses, SARS-CoV-2 and monkeypox virus.
  2. Systematically mapping epidemiological and clinical features of emerging viruses infections by employing multiple bioinformatics analyzing approaches.

SCIENTIFIC TRAININGS & EDUCATION
  • 2018-11-01 - 2023-06-13

    PhD
    Erasmus University Medical Center, Rotterdam, The Netherlands
  • 2015-09-01 - 2018-07-01

    Master
    Shandong Agricultural University, Taian, China
  • 2011-09-01 - 2015-07-01

    Bachelor
    Shandong Agricultural University, Taian, China

POSITIONS
No position available
KEY PUBLICATIONS | ALL PUBLICATIONS

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q.

Publication: Cell Research. 2022 Mar;32(3):322-324.


Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations

Li P, de Vries AC, Kamar N, Peppelenbosch MP, Pan Q.

Publication: Lancet Microbe. 2022 Mar 15. Online ahead of print.


Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids

Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, Pan Q.

Publication: Science Advances. 2022 Jan 21;8(3):eabj5908.


Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses

Pengfei Li, Aqsa Ikram, Maikel P Peppelenbosch, Zhongren Ma, Qiuwei Pan

Publication: Clinical Infectious Diseases. 2021 Aug 2;73(3):554-555.


Estimating global epidemiology of low pathogenic human coronaviruses relating to the COVID-19 context

Pengfei Li, Jiaye Liu, Zhongren Ma, Wichor M Bramer, Maikel P Peppelenbosch, Qiuwei Pan

Publication: The Journal of Infectious Diseases. 2020 Jul 23;222(4):695-696.